Ketotifen–metformin physical complex

The Ketotifen–metformin physical complex is not a biological target such as a receptor or enzyme, but rather a combination or formulation of two established pharmacological agents: ketotifen and metformin. Ketotifen is a second-generation non-competitive H1-antihistamine and mast cell stabilizer primarily used in the treatment of asthma and allergic conditions. Metformin is a biguanide antihyperglycemic agent that serves as the first-line medication for the treatment of type 2 diabetes by inhibiting hepatic glucose production and increasing peripheral glucose uptake. In research contexts, the physical complex or co-administration of these two drugs is often explored for potential synergistic effects in treating metabolic disorders or inflammatory diseases where mast cell activity and insulin resistance intersect. Because it represents a drug-drug pairing rather than a protein or nucleic acid target, it does not possess a single biological function or molecular classification. Instead, its properties are a composite of the individual pharmacodynamics of its constituents, targeting the H1 receptor and the AMPK pathway simultaneously.

Other names

Ketotifen-metformin combinationKetotifen and metformin co-administration

This is a physical complex of two distinct drugs rather than a single biological target. Ketotifen acts as a selective H1-receptor antagonist and mast cell stabilizer, while Metformin decreases hepatic glucose production and improves insulin sensitivity via AMPK activation. Research into their combination often focuses on synergistic effects in metabolic or inflammatory conditions.